Learn about the Trial to Assess Chelation Therapy 2 (TACT2) in this free presentation from the study chairman, Dr. Gervasio Lamas. Audio included.
Chelation therapy has long been scorned by many in the medical community. But after a major study suggested it was somewhat effective for heart disease, the alternative health treatment is once again going under the microscope. A second study called TACT 2 (Trial to Assess Chelation Therapy) will assess chelation’s heart-health benefits for patients with diabetes.
|Title||Low-level lead exposure and mortality in US adults:
a population-based cohort study
|Journal||The Lancet Public Health|
|Authors||Lanphear BP, Rauch S, Auinger P, Allen RW, Hornung RW|
|Link to article|
Lead exposure is a risk factor for cardiovascular disease mortality, but the number of deaths in the USA attributable to lead exposure is poorly defined. We aimed to quantify the relative contribution of environmental lead exposure to all-cause mortality, cardiovascular disease mortality, and ischaemic heart disease mortality. Our findings suggest that low-level environmental lead exposure is an important, but largely overlooked, risk factor for cardiovascular disease mortality in the USA. A comprehensive strategy to prevent deaths from cardiovascular disease should include efforts to reduce lead exposure.
Lead exposure may be responsible for nearly 10 times more deaths in the United States than previously thought, according to a new study from The Lancet Public Health.
Dr. Jeff Baker, of Clinical Research Prime in Idaho Falls, Idaho, explains how removing toxic metals from the body with chelation therapy could help patients with cardiovascular issues. His clinic is a participating site for TACT2.
TACT2 investigator Dr. Richard Nahas will present a free information session on diabetes, heart disease, and the TACT2 study on Tuesday, February 13, 7:00–8:30 p.m., at Ben Franklin Place in Ottawa, ON. RSVP required. Contact 613.727.7246 or firstname.lastname@example.org for more information.
Listen to Dr. Nahas talk about the history, goals, and significance of TACT2 in the video below.
|Title||Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review|
|Journal||Cardiovascular Drugs and Therapy|
|Authors||Mathew RO, Schulman-Marcus J, Nichols EL, Newman JD, Bangalore S, Farkouh M, Sidhu MS|
|Link to article|
Chelation therapy, typically used to remove heavy metal toxins, has also been controversially used as a treatment for coronary artery disease. The first Trial to Assess Chelation Therapy (TACT) aimed to provide evidence on chelation therapy’s potential for benefit or harm. Although TACT had some significant results, the trial does not provide enough evidence to recommend routine chelation therapy and has limitations. The second TACT was recently funded reigniting a discussion about the value of chelation therapy, its efficacy, and allocation of research resources. Despite limited evidence, patients continue to pursue chelation therapy as a treatment for coronary artery disease. As the medical community has a responsibility to understand all treatments patients pursue, it is important to comprehensively appraise chelation therapy for cardiovascular disease. Understanding the background of heavy metal toxicity, the putative target of chelation therapy, on the cardiovascular system is important to contextualize the role of chelation therapy in cardiovascular disease prevention. We review the clinical evidence of heavy metal toxicity and cardiovascular disease, and available clinical trial data on use of chelation therapy to minimize the cardiovascular burden of heavy metal toxicity.
|Title||Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT)|
|Journal||American Heart Journal|
|Authors||Omar M. Issa, DO, Rhonda Roberts, MPH, Daniel B. Mark, MD, MPH, Robin Boineau, MD, Christine Goertz, DC, PhD, Yves Rosenberg, MD, MPH, Eldrin F. Lewis, MD, Erminia Guarneri, MD, Jeanne Drisko, MD, Allan Magaziner, DO, Kerry L. Lee, PhD, Gervasio A. Lamas, MD|
|Link to article|
In a prespecified subgroup analysis of participants not on statin therapy at baseline in the TACT, a high-dose complex oral multivitamins and multimineral regimen was found to have a large unexpected benefit compared with placebo. The regimen tested was substantially different from any vitamin regimen tested in prior clinical trials. High-dose oral multivitamin and multimineral supplementation seem to decrease combined cardiac events in a stable, post-MI population not taking statin therapy at baseline. These unexpected findings are being retested in the ongoing TACT2.
Los diabéticos Tipo 2 con historial de paro cardíaco pueden encontrar una solución a sus complicaciones. ¿La clave? Una droga desarrollada en la década de 1950.
Type 2 diabetics with a history of cardiac arrest might find a solution to their complications. The key? A drug developed in the 1950s.